<DOC>
	<DOCNO>NCT02342392</DOCNO>
	<brief_summary>The purpose study evaluate pterygium vascularity size intralesional ranibizumab injection evaluate recurrence rate follow pterygium excision surgery .</brief_summary>
	<brief_title>Intralesional Ranibizumab Pterygium Vascularity , Size Recurrence Rate : Pilot Study</brief_title>
	<detailed_description>The purpose study : 1 . Compare vascularity primary pterygium 1 week intralesional ranibizumab ( 0.3 mg/0.03 mL ) injection . 2 . Compare size primary pterygium 1 week intralesional ranibizumab ( 0.3 mg/0.03 mL ) injection . 3 . Compare recurrence rate 1 year pterygium excision surgery group without intralesional ranibizumab injection .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>All patient primary pterygium . Grade T3 ( fleshy ) pterygium . Patients ocular surface disorder . Previous ocular surgery trauma . History systemic thromboembolic event . Pregnant woman lactate mother .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pterygium</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>recurrence</keyword>
	<keyword>vascularity</keyword>
	<keyword>size</keyword>
</DOC>